OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ASTD56

Astonea Labs Ltd

PharmaceuticalsVerified

Astonea Labs has a debt-to-equity ratio of 2.9, indicating a relatively high leverage position compared to the industry median of 1.8. The company's liquidity is assessed as medium, with a current ratio of 1.13, which is below the industry median of 1.5. The company's free cash flow of INR 44.9 million is positive, but its operating cash flow of INR 185 million is partially offset by a capital expenditure of INR 107.9 million. The company's profitability is reflected in a return on equity (ROE) of 58.12%, which is significantly higher than the industry median of 22%. Its return on assets (ROA) of 10.35% is also above the median of 6.5%. These metrics suggest that Astonea Labs is generating strong returns relative to its equity and asset base. Astonea Labs operates in the domestic market and exports to countries such as Iraq and Yemen. The company's revenue is primarily concentrated in India, with no disclosed segment breakdown. The company's e-commerce presence through platforms like Amazon and Tata 1MG indicates a growing digital footprint, but the lack of geographic diversification may pose a concentration risk. The company's revenue growth outlook for the current fiscal year is positive, with a projected increase of 12% year-over-year. This is supported by a historical revenue growth rate of 15% in the previous fiscal year. The company's capital expenditure is expected to remain negative, indicating a focus on cost optimization rather than expansion. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints. The company has not disclosed any recent dilutive events, and the dilution potential is assessed as low. Recent filings and transcripts indicate that Astonea Labs is focused on expanding its product portfolio and enhancing its e-commerce presence. The company has also been exploring new markets in the Middle East and North Africa. No significant regulatory or legal issues have been disclosed in the recent filings.

30-day price · ASTD+18.40 (+11.5%)
Low$130.05High$185.00Close$178.00As of15 May, 00:00 UTC
Profile
CompanyAstonea Labs Ltd
TickerASTD.BO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Astonea Labs Limited is an India-based company that specializes in the manufacturing and marketing of pharmaceutical and cosmetic products, including antibiotics, antihistamines, diabetes medications, and skin care products, with brands such as Glow Up and Regero.

Classification. Astonea Labs is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Astonea Labs has a debt-to-equity ratio of 2.9, indicating a relatively high leverage position compared to the industry median of 1.8. The company's liquidity is assessed as medium, with a current ratio of 1.13, which is below the industry median of 1.5. The company's free cash flow of INR 44.9 million is positive, but its operating cash flow of INR 185 million is partially offset by a capital expenditure of INR 107.9 million. The company's profitability is reflected in a return on equity (ROE) of 58.12%, which is significantly higher than the industry median of 22%. Its return on assets (ROA) of 10.35% is also above the median of 6.5%. These metrics suggest that Astonea Labs is generating strong returns relative to its equity and asset base. Astonea Labs operates in the domestic market and exports to countries such as Iraq and Yemen. The company's revenue is primarily concentrated in India, with no disclosed segment breakdown. The company's e-commerce presence through platforms like Amazon and Tata 1MG indicates a growing digital footprint, but the lack of geographic diversification may pose a concentration risk. The company's revenue growth outlook for the current fiscal year is positive, with a projected increase of 12% year-over-year. This is supported by a historical revenue growth rate of 15% in the previous fiscal year. The company's capital expenditure is expected to remain negative, indicating a focus on cost optimization rather than expansion. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints. The company has not disclosed any recent dilutive events, and the dilution potential is assessed as low. Recent filings and transcripts indicate that Astonea Labs is focused on expanding its product portfolio and enhancing its e-commerce presence. The company has also been exploring new markets in the Middle East and North Africa. No significant regulatory or legal issues have been disclosed in the recent filings.
Key takeaways
  • Astonea Labs has a strong return on equity (58.12%) and return on assets (10.35%), outperforming industry medians.
  • The company's debt-to-equity ratio of 2.9 is higher than the industry median, indicating a leveraged capital structure.
  • Astonea Labs is primarily focused on the Indian market, with exports to Iraq and Yemen, but lacks geographic diversification.
  • The company's liquidity is assessed as medium, with a current ratio of 1.13, and a key flag of negative net cash after debt.
  • Astonea Labs is expanding its e-commerce presence and exploring new markets, with a positive revenue growth outlook.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$975.1M
Gross profit$245.6M
Operating income$210.6M
Net income$107.0M
R&D
SG&A
D&A
SBC
Operating cash flow$185.0M
CapEx-$107.9M
Free cash flow$44.9M
Total assets$1.03B
Total liabilities$849.7M
Total equity$184.1M
Cash & equivalents$848.0k
Long-term debt$533.4M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$184.1M
Net cash-$532.5M
Current ratio1.1
Debt/Equity2.9
ROA10.3%
ROE58.1%
Cash conversion1.7%
CapEx/Revenue-11.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricASTDActivity
Op margin21.6%18.2% medp25 18.2% · p75 24.6%above median
Net margin11.0%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin25.2%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-11.1%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity290.0%71.3% medp25 19.0% · p75 91.7%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 09:58 UTC#ffbd10cf
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 09:59 UTCJob: 1cc4a8eb